Middle East and North Africa Advanced Wound Care Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Dressings, Devices, and Biological Skin Substitutes), Wound Type (Chronic Wou

According to our new research study on “Middle East and North Africa Advanced Wound Care Market Forecast to 2031 -Regional Analysis - by Product Type, Wound Type, and End User,” the market is anticipated to grow from US$ 197.65 million in 2024 to US$ 270.25 million by 2031; the market is expected to register a CAGR of 4.7% from 2025 to 2031. The Middle East and North Africa advanced wound care market growth are attributed to the rise in demand for minimally invasive procedures, technological advancement and product innovations, along with societal shifts toward youthful appearance and preventive care. Advanced wound care is a set of medical treatments and products that facilitate the healing process of chronic, complicated, or resistant wounds to healing, e.g., diabetic foot ulcers, pressure injuries, and venous leg ulcers, which have not responded to standard dressings or basic care. The Middle East and North Africa advanced wound care market is categorized into the UAE, Saudi Arabia, Egypt, Iraq, Algeria, Jordan, and the Rest of MENA. An increasing prevalence of chronic diseases such as diabetes and obesity has led to a rise in diabetic foot ulcers and pressure ulcers, boosting demand for wound care solutions. Additionally, an aging population contributes to the need for advanced wound management. Improvements in healthcare infrastructure, growing awareness of modern wound care technologies, and increasing government expenditures on healthcare are driving market expansion. The region is witnessing a shift from traditional wound care methods to more efficient and technologically advanced products such as hydrocolloids, foam dressings, and negative pressure wound therapy. The expansion of private healthcare providers and increased medical tourism, particularly in the Gulf Cooperation Council (GCC) countries, accelerates the demand for advanced wound care management solutions. According to data published by the IDF in 2024, ~5,344,600 adults in the nation were affected by diabetes, accounting for a prevalence rate of 23.1% of the total population and heightening the incidence of chronic wounds, such as diabetic foot ulcers (DFU). The risk of developing foot ulcers is ~ 25% in individuals with diabetes. These conditions, exacerbated by neuropathy and poor circulation, necessitate hydrocolloid dressings, hydrogels, and antimicrobial films to accelerate healing and avert amputations. Thus, an increase in the diabetic population drives the demand for DFU wound care products in the country. According to a qualitative study published in June 2022 titled “Noncommunicable diseases and health system responses in Saudi Arabia: focus on policies and strategies,” chronic diseases are responsible for 73% of total deaths. Therefore, a large portion of the population is expected to suffer from chronic diseases, developing a risk of pressure ulcers. The proportion of the elderly (65+) is increasing, which means more individuals with reduced mobility, comorbidities, slower healing, and a greater risk of wounds such as pressure sores. An increased life expectancy and the growing burden of non‑communicable diseases put pressure on the health system to provide better wound care. Vision 2030's ambitious reforms allocate US$ 65 billion toward infrastructure modernization, including 21 nationwide health clusters and expanded e-health services. This fiscal commitment, representing a significant portion of GDP in health and social development, facilitates the procurement of technologies such as NPWT devices and bioengineered skin substitutes, which are now mandated in Ministry of Health facilities to standardize care and minimize hospital readmissions. In May 2024, TVM Capital Healthcare closed the US$ 250 million Afiyah Fund to bolster local adoption of innovative solutions, such as DEBx Medical's DEBRICHEM debridement agent. It is tailored for chronic wounds in the region. It is set for commercialization in Saudi Arabia, aiming to shorten supply chains and lower costs through the "Made in Saudi" initiative. The growth of the advanced wound care market in Saudi Arabia is driven by a heavy chronic disease burden, increasing aging, government investment in healthcare infrastructure, the availability of technology, regulatory support, and a shift toward outpatient/home-based and telehealth models. Bioactive and Regenerative Therapies to Provide Market Opportunities in Future Bioactive and regenerative therapies harness stem cells, exosomes, platelet-rich plasma (PRP), and bioengineered scaffolds to stimulate tissue regeneration. This process helps to combat chronic inflammation and accelerate closure of non-healing wounds such as DFUs and pressure injuries. It offers superior outcomes compared to traditional dressings in a region where chronic wounds affect 12% of the population. These therapies promote angiogenesis, collagen deposition, and epithelial migration, with clinical trials showing 50-70% faster healing rates. The IDF's 2025 MENA Diabetes Complications Survey reports that exosome-loaded hydrogels reduced DFU recurrence by 35% in 1,000 Egyptian patients, utilizing mesenchymal stem cell-derived vesicles to achieve anti-fibrotic effects. Dubai's 2024-2026 Stem Cell Research Program, funded by US$ 150 million from the Mohammed bin Rashid Al Maktoum Knowledge Foundation, has applied PRP-augmented acellular dermal matrices in 300 surgical wounds. According to the UAE Ministry of Health and Prevention, they achieved a 60% graft take rate compared to 40% in controls in 2025. According to the 2025 report in the Saudi Journal of Biological Sciences, King Abdulaziz University Hospital in Saudi Arabia trialed bioactive growth factor sprays in 2025 on 150 venous leg ulcers, achieving 45% complete healing within 8 weeks, compared to 20% for standard care. It was supported by the US$ 1 billion National Center for Stem Cell Research, launched in 2023. Morocco's 2024 World Bank-partnered regenerative initiative introduced marine collagen scaffolds from Atlantic algae for burn victims in Casablanca. According to the Moroccan Ministry of Health (2025), this is used in 500 burn cases, resulting in a reduction in scar tissue, which addresses the 10,000 annual burns caused by industrial accidents. These innovations, combined with the use of 3D bioprinting for patient-specific grafts, support the UN Sustainable Development Goals and reflect the growing number of regenerative MedTech patents emerging from the region. Ethical frameworks, including Egypt's 2025 bioethics guidelines, ensure equitable access to and integration of therapy in public hospitals, leading to the prevention of approximately 200,000 amputations annually. The US Food and Drug Administration, National Institute of Health, are among the primary and secondary sources referred to while preparing the Middle East and North Africa advanced wound care market report.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East and North Africa Advanced Wound Care market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East and North Africa Advanced Wound Care market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East and North Africa Advanced Wound Care market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution Show more